Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chazhu Xiaozhi decoction for non-alcoholic fatty liver disease
ChiCTR2400085096Phase 2Not yet recruiting
- Sponsor
- Shanghai Municipal Hospital of Traditional Chinese Medicine
- Start
- May 2024
- Countries
- 1
01
Overview
Phase 2, randomised trial of Chazhu Xiaozhi decoction in metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Shanghai Municipal Hospital of Traditional Chinese Medicine. Primary endpoints: controlled attenuation parameter and traditional Chinese medicine syndrome scale. Planned start May 2024; status: not yet recruiting.
02
Drugs
Chazhu Xiaozhi decoction
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR2400085096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085096.